These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29905808)

  • 1. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
    Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
    J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.
    Lê MP; Chaix ML; Raffi F; Chevret S; Gallien S; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
    Br J Clin Pharmacol; 2019 Jan; 85(1):277-280. PubMed ID: 30421447
    [No Abstract]   [Full Text] [Related]  

  • 3. Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight).
    Molina JM; Gallien S; Chaix ML; El Abbassi EM; Madelaine I; Katlama C; Valin N; Delobel P; Desseaux K; Peytavin G; Saillard J; Raffi F; Chevret S;
    J Antimicrob Chemother; 2018 Aug; 73(8):2129-2136. PubMed ID: 29860402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
    Jackson A; Else L; Higgs C; Karolia Z; Khoo S; Back D; Devitt E; Pozniak A; Boffito M
    HIV Clin Trials; 2018 Feb; 19(1):31-37. PubMed ID: 29189101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children.
    Bastiaans DET; Geelen SPM; Visser EG; van der Flier M; Vermont CL; Colbers APH; Roukens M; Burger DM; van Rossum AMC;
    Pediatr Infect Dis J; 2018 Oct; 37(10):1008-1010. PubMed ID: 29474261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
    Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
    Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
    Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Fletcher CV; Acosta EP;
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):294-296. PubMed ID: 27103489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
    Crauwels HM; Kakuda TN; Ryan B; Zorrilla C; Osiyemi OO; Yasin S; Brown K; Verboven P; Hillewaert V; Baugh B
    HIV Med; 2016 Oct; 17(9):643-52. PubMed ID: 27187894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
    Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
    Ghosn J; Slama L; Chermak A; Houssaini A; Lambert-Niclot S; Schneider L; Fourn E; Duvivier C; Simon A; Courbon E; Murphy R; Flandre P; Peytavin G; Katlama C;
    J Med Virol; 2013 Jan; 85(1):8-15. PubMed ID: 23024008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
    Di Yacovo MS; Moltó J; Ferrer E; Curran A; Else L; Gisslén M; Clotet B; Tiraboschi JM; Niubò J; Vila A; Zetterberg H; Back D; Podzamczer D
    J Antimicrob Chemother; 2015 May; 70(5):1513-6. PubMed ID: 25608583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.
    Colbers A; Greupink R; Litjens C; Burger D; Russel FG
    Clin Pharmacokinet; 2016 Mar; 55(3):381-96. PubMed ID: 26369773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
    Zorrilla CD; Wright R; Osiyemi OO; Yasin S; Baugh B; Brown K; Coate B; Verboven P; Mrus J; Falcon R; Kakuda TN
    HIV Med; 2014 Jan; 15(1):50-6. PubMed ID: 23731450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
    Moltó J; Curran A; Miranda C; Challenger E; Santos JR; Ribera E; Khoo S; Valle M; Clotet B
    J Antimicrob Chemother; 2018 Mar; 73(3):732-737. PubMed ID: 29237008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
    Cattaneo D; Gervasoni C; Cozzi V; Baldelli S; Fucile S; Meraviglia P; Landonio S; Boreggio G; Rizzardini G; Clementi E
    Pharmacol Res; 2012 Feb; 65(2):198-203. PubMed ID: 21958880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darunavir/cobicistat once daily for the treatment of HIV.
    Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.